Mice de®cient for the mismatch repair (MMR) gene Msh2 show accelerated tumourigenesis and a reduced apoptotic response to DNA damage of methylation type. Here we examine the eect of mutation for Msh2 on in vivo mutation frequencies in the intestine as determined by loss of function at the Dolichos bi¯orus (Dlb-1) locus. Spontaneous mutation frequencies were scored in cohorts of ageing mice either wild type or mutant for Msh2. In mice less than 1 year old, mutation frequencies were only elevated in Msh2 null mice. However, beyond this age heterozygous Msh2 mice showed signi®cantly higher mutation frequencies than controls. These ®ndings implicate a gene dose dependent requirement for Msh2 in mutation suppression and prompted an analysis of young Msh2 mutants following exposure to DNA damage. Following exposure to N-methyl-N'-nitro-Nnitrosoguanidine (MNNG), Msh2 de®cient mice show a reduced apoptotic response and an increase in mutation frequency. Heterozygotes did not dier from controls. Following exposure to cisplatin, no signi®cant elevation was seen in mutation frequencies, even within homozygotes. This is particularly surprising given the association between cisplatin resistance and MMR de®ciency. These ®ndings therefore demonstrate a complex reliance upon functional Msh2 in mutation surveillance. We have identi®ed three separate scenarios. First, where retention of both Msh2 alleles over an extended period of time appears critical to the suppression of spontaneous mutation; second, 3 weeks following exposure to MNNG, where only complete loss of Msh2 results in elevated mutation; and ®nally following cisplatin exposure, where induced levels of mutation are independent of Msh2 status. Oncogene 
Mice de®cient for the mismatch repair (MMR) gene Msh2 show accelerated tumourigenesis and a reduced apoptotic response to DNA damage of methylation type. Here we examine the eect of mutation for Msh2 on in vivo mutation frequencies in the intestine as determined by loss of function at the Dolichos bi¯orus (Dlb-1) locus. Spontaneous mutation frequencies were scored in cohorts of ageing mice either wild type or mutant for Msh2. In mice less than 1 year old, mutation frequencies were only elevated in Msh2 null mice. However, beyond this age heterozygous Msh2 mice showed signi®cantly higher mutation frequencies than controls. These ®ndings implicate a gene dose dependent requirement for Msh2 in mutation suppression and prompted an analysis of young Msh2 mutants following exposure to DNA damage. Following exposure to N-methyl-N'-nitro-Nnitrosoguanidine (MNNG), Msh2 de®cient mice show a reduced apoptotic response and an increase in mutation frequency. Heterozygotes did not dier from controls. Following exposure to cisplatin, no signi®cant elevation was seen in mutation frequencies, even within homozygotes. This is particularly surprising given the association between cisplatin resistance and MMR de®ciency. These ®ndings therefore demonstrate a complex reliance upon functional Msh2 in mutation surveillance. We have identi®ed three separate scenarios. First, where retention of both Msh2 alleles over an extended period of time appears critical to the suppression of spontaneous mutation; second, 3 weeks following exposure to MNNG, where only complete loss of Msh2 results in elevated mutation; and ®nally following cisplatin exposure, where induced levels of mutation are independent of Msh2 status. Oncogene Keywords: mismatch repair; apoptosis; mutation; heterozygosity; cisplatin; alkylation Structural distortions produced by nucleotides which are either unpaired or paired with non-complementary nucleotides are recognized by proteins encoded by the mismatch repair genes. Several members of this family of genes have been characterized within Saccharomyces cerevisiae, which led to the identi®cation of mammalian homologues. Six human mismatch repair genes have been cloned, MSH2, MLH1, PMS1, PMS2, MSH3 and MSH6 (Kinzler and Vogelstein, 1996; Wheeler et al., 2000) . Constitutive inactivation of these genes has been associated with the development of cancer, the best characterized relationship being between the inherited cancer-susceptibility syndrome of Hereditary Nonpolyposis Colorectal Cancer (HNPCC) and germline mutations in MSH2, MLH1 and PMS2 (Nicolades et al., 1994; Kinzler and Vogelstein, 1996) . Mice have been produced bearing targeted inactivations of the Mlh1, Msh2, and Pms2 genes. Homozygous mice of these mutant strains are viable but prone to the development of dierent types of neoplasia. All of these mutant strains develop lymphoma, however they dier in their susceptibility to intestinal neoplasia, which only develops in Mlh1 and Msh2 de®cient mice (De Wind et al., 1995; Reitmair et al., 1996; Prolla et al., 1998) . As such, Msh2 and Mlh1 homozygotes can be considered reasonably good models of HNPCC. By contrast, mice heterozygous for Msh2 and Mlh1 do not show reduced survival compared to wild type controls, nor are they predisposed increased intestinal neoplasia. They are, however characterized by increased tumorigenesis. Surprisingly when these tumours were examined for Loss of Heterozygosity (LOH) only one out of 71 had lost the remaining copy of Msh2 and this was the only tumour to exhibit microsatellite instability (MI), indicating that the majority of tumours retained heterozygosity for Msh2 (De Wind et al., 1998) . These results are therefore consistent with a heterozygous eect of Msh2.
There are currently two possible biological mechanisms underlying the relationship between MMR de®ciency and neoplasia. The ®rst of these arises out of the MMR proteins de®ning role in mediating DNA repair. MSH2 recognizes mismatched nucleotides as a heterodimer with MSH6 and insertion/deletion loops with MSH3 (Buermeyer et al., 1999) . In what is assumed to be a direct consequence of failure of these processes, Msh27/7 cells exhibit a mutator phenotype and microsatellite instability (De Wind et al., 1995; Reitmair et al., 1997) . These data support the concept that failed recognition and repair of mismatch lesions leads directly to an increase in mutation frequency and thereby to malignancy. A second possible mechanism derives from recent studies which have shown that loss of the mismatch repair gene Msh2 impairs the apoptotic response to alkylating agents in a variety of systems (Toft et al., 1999; Hickman and Samson, 1999) . Consistent with this, cells de®cient in MMR have been shown to be resistant to a number of clinically important drugs, such as cisplatin, temozolomide and doxorubicin (Fink et al., 1998) . This raises the possibility that increased mutation frequencies may partly arise from failed clearance of DNA damage bearing cells. Currently, there is little direct evidence in support of this hypothesis, although it is clear that Msh2 de®ciency does lead to an elevation in mutation frequencies following exposure to DNA damage (Andrew et al., 1998; Toft et al., 1999) . Toft et al. (1999) have demonstrated that (in a model system) a component of this increase is attributable to increased cell survival. Thus, although Msh2 clearly plays a role in mediating cell death, the precise relationship between the ability to engage apoptosis and mutation surveillance remains relatively poorly de®ned.
To investigate the in vivo consequences of heterozygosity at the Msh2 locus and to further explore the relationship between apoptosis and mutation surveillance, we have examined the gene dependency of these two endpoints in the small intestine of mice wild type, heterozygous and nullizygous for Msh2. These studies were performed both at spontaneous levels of damage and following exposure to the DNA damaging agents MNNG and cisplatin.
We ®rst scored mutation frequency at the Dlb-1 locus at spontaneous levels of DNA damage over a 13 month time course (Figure 1 ). The Dlb-1 assay was performed as previously described (Winton et al., 1988) . For this assay, experimental cohorts were derived by backcrossing the Msh2 mutants to two dierent C57Bl/6 strains, one of which was homozygous for the Dlb-1a allele and one of which was homozygous for the Dlb-1b allele. Mice were subsequently intercrossed from these two lines to generate mice heterozygous at the Dlb-1 locus and segregating for all possible Msh2 genotypes. Loss of the Dlb-1b allele was then scored per 10 000 villi.
Msh2 null mice exhibited a higher mutation frequency than wild type controls and Msh2 heterozygous mice. Msh2 null mice showed a marked increase in mutation frequency from 4 to 8 weeks: a period where there is a signi®cant increase in the number of crypts (Shoemaker et al., 1995) . Surprisingly, beyond this time point there was no further increase in mutation frequency. This may re¯ect selection for mice with a reduced predisposition to neoplasia (and potentially reduced mutation frequencies) at the later time points as the peak incidence of neoplasia occurs at 3 ± 4 months.
The most intriguing result is the increase in mutation frequency in the heterozygotes aged over 12 months. Similar results have been shown using very sensitive mutation screens in Msh2 and Mlh1 heterozygous diploid yeast (Shcherbakova and Kunkel, 1999; Drotschmann et al., 1999 Drotschmann et al., , 2000 . The authors of these studies argued that this increased mutation frequency occurred due to loss of heterozygosity in a small population of the heterozygote cells. However, although LOH at the Msh2 locus cannot be formally ruled out as the mechanism underlying the increase in the aged hemizygotes, we believe this to be unlikely as this requires two mutations (inactivation of the remaining Msh2 allele and subsequent inactivation of Dlb-1b) to occur sequentially within the same stem cell. Wild type cells accumulate on average one additional mutation per 10 000 crypts each month (Winton et al., 1988) . If we assume a null hypothesis and that heterozygosity for Msh2 plays no direct role in suppressing mutation, and furthermore that Msh2 is inactivated at a similar rate to Dlb1, then after 13 months there would be approximately 13 Msh2 null clones per 10 000 crypts. Our analysis shows Msh2 de®ciency increases the mutation frequency to, at maximum, less than 10 times that found in wild type cells (the highest fold dierence of 9.6 was observed at 1 month). This indicates that the additional mutation burden from the Msh2 null clones would be less than 1 mutation per 10 000 villi. This increase is clearly insucient to account for the actual observed increase, strongly implying that the elevation in mutation frequency is occurring as a direct consequence of Msh2 heterozygosity.
We interpret the eect of heterozygosity at the Msh2 locus as leading to a constant but small increase in mutability which only becomes evident over a long period of elapsed time (in this instance 12 months of age). However, it remains formally possible that heterozygosity for Msh2 may result in the mice becoming hypermutable at old age, a hypothesis which we have not addressed in this study, but one which could be addressed by future experiments.
Figure 1 Spontaneous Dlb-1 mutation frequencies scored per 10 000 villi in mice wild type (crosses), heterozygous (circles) and homozygous null (square points) for Msh2. Each point represents at least three mice. At ages over 1 year, heterozygous mice (n=12, mean=24) have a signi®cantly higher mutation frequency than wild type (n=8, mean=11) mice. P=0.04, Mann Whitney U test)
The data presented here parallels other studies which have suggested gene dose sensitivity for Msh2 dependent responses. These include analyses of the level of DNA lesions and the apoptotic response following exposure to low level radiation treatment (DeWeese et al., 1998) , and also by studies which have shown very low rates of LOH at the Msh2 locus in tumours arising in Msh2 hemizygotes (De Wind et al., 1998) .
The above observations prompted analysis of the apoptotic response, to determine if this response was also Msh2 gene dose sensitive. Apoptosis of enterocytes within the crypts of Lieberkuhn was examined at 6 h after drug exposure (Figure 2 ). This analysis was performed on mice aged 8 ± 12 weeks. We have previously established that this time point coincides with the peak induction of apoptosis within this structure (see Toft et al., 1999; Sansom and Clarke, 2000) . Consistent with previous results Msh2 de®cient mice showed a reduced apoptotic response following exposure to MNNG whilst there was normal apoptotic response in wild type and Msh2 heterozygous mice (P=0.38). Following exposure to cisplatin, no dierence was observed between hemizygotes and wild type mice (P=0.20, Mann Whitney U), a result which is perhaps not unexpected as Msh2 null mice show only a marginal reduction in the apoptotic response compared to wild type controls (Toft et al., 1999) . The failure to observe high levels of MMR-dependent cell death following cisplatin exposure contradicts the scenario reported for ovarian cancer cells, where resistance to cisplatin is associated with loss of MMR function and restoration of MMR causes re-sensitization. This must either be a re¯ection of the rather subtle changes in the ability to engage apoptosis, or must implicate nonapoptotic MMR-dependent mechanisms in long term cell survival.
Despite the presence of a normal, intact apoptotic response in Msh2 heterozygotes it remained possible that there could be a gene dosage eect in mutation induction following these agents. Previously Shcherbakova and Kunkel (1999) have demonstrated signi®cant increases in mutation frequency in yeast heterozygous for Mlh1 following exposure to either bleomycin or UV irradiation. These phenomena were assumed to arise from damage enhanced LOH. Furthermore, studies using Mlh1 heterozygous mice following MNU (Nmethyl-N-nitrosourea) exposure have revealed increased rates of tumourigenesis compared to wild type controls (Kawate et al., 2000) . We therefore investigated mutation frequency at the Dlb-1 locus in young (8 ± 12 weeks old) Msh2 mutant mice following treatment with either MNNG (Sigma) or cisplatin (David Bull Laboratories) (Figure 3) . Mutation was scored 3 weeks post i.p. injection. Following exposure to 50 mg/kg MNNG we observed a signi®cant increase in mutation frequency in Msh2 null mice compared to controls (Mann Whitney U test, P=0.0414), but not in heterozygotes (Mann Whitney U test, P=0.17). These results parallel those obtained following exposure to the alkylating agent Temozolomide (Toft et al., 1999) , con®rming that Msh2 normally suppresses mutation following damage of alkylation type but also showing that this response is not Msh2 gene-dose sensitive. Following cisplatin exposure Msh2 nulls showed increased mutation frequencies relative to controls and heterozygous mice, however these increases could entirely be accounted for by the increase in spontaneous mutation frequency. These results therefore fail to demonstrate a role for Msh2 in mutation surveillance following cisplatin treatment and question the signi®cance of mismatch repair in the clearance of cisplatin-induced DNA damage in normal cells. Our ®ndings complement recent studies by Branch et al. (2000) , who demonstrated that loss of MMR was only a minor contributor to cisplatin resistance in ovarian tumour cell lines.
The studies reported here have been performed in normal intestinal enterocytes. It remains possible that the reliance upon functional MMR for mutation surveillance markedly diers between normal and neoplastic cells. Pertinently, Strathdee et al. (2001) have shown that mouse embryonic ®broblasts de®cient for Msh2 still undergo a G2 arrest following cisplatin treatment in marked contrast to MMR de®cient tumour cell lines which lose this checkpoint (Brown et al., 1997) .
In conclusion, we demonstrate an extremely complex reliance upon Msh2 in mutation surveillance. We show that Msh2 is critical in monitoring spontaneous levels of DNA damage, such that even a 50% reduction in Msh2 gene dosage can elevate mutation frequency. We show that this reliance upon Msh2 in response to spontaneous levels of DNA damage is not directly re¯ected by gene dependencies in either the apoptotic response or mutation burden following acute DNA damage. We show that Msh2 de®ciency leads to an increase in the in vivo mutation frequency following MNNG treatment, but remarkably that this is not the case following exposure to cisplatin. Taken in the context of the recent proliferation of data relating to MMR-dependent DNA damage responses, these observations show that reliance upon functional MMR is highly lesion type dependent. They also challenge our understanding of MMR-dependent suppression of mutation, perhaps partly because MMR dependent responses are usually interpreted in an experimental setting following high, non physiological levels of DNA damage. Clearly, although such scenarios may directly relate to the response to chemotherapeutics in a clinical setting, they may not accurately re¯ect the reliance upon MMR in normal tissues exposed to low levels of spontaneous damage.
